NAVB should have been mentioned in this article:

http://www.forbes.com/sites/greatspeculations/2013/10/08/five-stocks-analysts-see-tripling-in-price/?partner=yahootix

I always have said expect the unexpected with NAVB. I never expected NAVB to be back in the 2.30s WITHOUT bad news.

Is Platinum-Montaur selling?

Is Crede shorting? If not, they would probably like to ring some necks in Dublin.

Is the European Approval in jeopardy? I think not, but this decline in advance of so many expected catalysts is ridiculous.

GLTA.

If anyone knows what interest rate the shorts are being charged as of today, I'd be very interested in knowing. The stock is trading as if shorts are being PAID to short it - as if there is not an 8% short interest rate, but rather an automatic gain of 8% just for shorting.

Of course. I thought you meant there was a date relating to NAVB exclusively. The market in general may well collapse within a week at this rate.

I am expecting European Approval next Friday - October 18th.
That date is 180 days after the last NAVB European regulatory checkpoint. It appears as if the shorts are maninpulating NAVB down as far as they can in anticipation of the stock going wild soon.

There is no good reason to short so aggressively other than limiting how high the stock can go on the next blockbuster PR.

May their necks be broken due to miscalculation.

GLTA

EXACTLY! By April 2014...with all of 2013 gone, April 2014 is the latest my own patience will tolerate. I see absolutely no good reason they didn't drill in 2013, let alone well into 2014.

Why would they delay drilling? Drilling is scheduled for April 2014 last I knew, and to delay even another month would create a terrible impression on the market as all of 2013 is going to pass by with few updates as it is. A delay by Tullow is the last thing we need.

I'm expecting aggressive smear articles and/or tactics from our pals the shorts ANYDAY NOW in an effort to depress the pps further prior to a coming steady flow of catalysts. Some rude surprise to distort the company is likely on the way - something like the Piper Jaffries article that put NAVB at 1.50/share.

Wouldn't it be nice if Brent Larson and the new IR firm did something to earn their money? I'm more surprised by the inaction of the company to stop the pps slide than I am the fact that the shorts are doing it.

GLTA.

Does everyone else think a run is impossible? One thing to remember with NAVB is that nothing is impossible and I say a run is PROBABLE.

Thanks for the response. Ameritrade has refused to allow me to buy BLLZ more than once as well.

GLTA.

Thanks for the response. Ameritrade has refused to allow me to buy BLLZ more than once as well.

GLTA.

I'm expecting a run to start as early as tommorow in anticipation of EU approval/partnership OCTOBER 18, 2013. IMO, the selling can't last and the shorting can't either. With all of the news over the past two months, it is unthinkable that we are buried in the 2.60s again.

Offerings sometimes create an illusion of weakness, but in the case of NAVB, informed investors know some of what the company is doing...and we can only wonder how many more pleasant surprises are on the horizon. I'm not selling a single share.

GLTA.

Excellent post umiak. The MC is being stifled in an attempt to create a panic. My hunch is that the CC will get the pps right back into the 2.80s.

I just tried to buy shares through Ameritrade and my trade was not allowed to process. I got the following explanation:

"Order cannot be processed due to a DTC chill restricting the ability to transfer a security and settle the trade."

Any ideas on when this will change? I would like to get 1,000,000 shares at the current ask...Please advise.

I spoke with a friend tonight who mentioned that an NAVB CC will be held this Friday morning at 10:00AM. Perhaps the company is going to announce what they plan to do with the $30 million they just raised. I believe there was a significant reason for the offering. Have others seen a PR about this for Friday 9/27?

Perhaps DDbuyer is not posting for a reason...a reason like he knows something that he cannot post. Something good of course...

One thing I know is that the date for European approval is October 18th. I have always said "EXPECT THE UNEXPECTED" with NAVB. We got it yesterday.

What if NAVB is acquiring another company (a smaller one with one or two products in development)?

What if NAVB is going to fund the RIGS trials on their own? The company did say that Q4 2013 was when we could expect a RIGS update. Regardless of the pps right now, the company seems to be in an excellent financial position.

The shorts continue to create opportunity. I know that for sure.

GLTA.

With this offering and the line of credit, the company has in excess of $50 million. Good things are on the way...and nonsense posts do not survive.

One possibility here is that the market in general will take notice of NAVB with the European Partnership and/or EU approval of Lymphoseek (or some other catalyst yet to come). Those buying now under 3.00 will be richly rewarded when the pps surges above 4.00 again.

If you want to make fast money with high risk, go to a casino. If you want to make sure money in the near future (less than 12 months) buy NAVB. LOL.

GLTA.

More news after hours:

4:30PM Navidea Biopharma: Independent investigators report Lymphoseek results in JAMA Otolaryngology Head and Neck Surgery (NAVB) 2.83 -0.05: Co announced that results from the Phase 3 clinical trial of Lymphoseek (technetium Tc 99m tilmanocept) Injection in Head and Neck Cancer (NEO3-06) at The Ohio State University Comprehensive Cancer Center -- James Cancer Hospital & Solove Research Institute were published in the current edition of the peer-reviewed journal, JAMA Otolaryngology Head and Neck Surgery, a publication of the American Medical Association. "The results, published independently by this single clinical trial site in our larger Phase 3 NE03-06 study, corroborate data for the ability of Lymphoseek to identify sentinel lymph nodes in head and neck squamous cell carcinoma," said Mark Pykett, VMD, PhD, CEO of Navidea. "As Navidea previously announced, Lymphoseek met the primary endpoint in the NE03-06 trial, where it correctly identified pathology-positive lymph nodes in 38 of 39 patients, demonstrating a statistically significant overall False Negative Rate of 2.56 percent. We look forward to additional presentations of the broader dataset from our NE03-06 Phase 3 clinical trial in the coming months. We have closed the study following a constructive FDA meeting and with the recommendation of the Data Safety Monitoring Committee. Based on the NEO3-06 study results and data analysis, we are working to file an sNDA for Lymphoseek by year end."

You raise excellent points. NAVB was once over 5.00 (May and June 2011) and then settled for a while in the 2.80 range around August 19, 2011 - right where we are now.

It was questionable shorting that made NAVB plunge.

My point? The outstanding share count at the time was around 90 million shares. The stock lost more than $2 per share for a net loss in market cap of approximately $180 million.

What is $14.4 million in fines spread over 23 firms when one stock can suffer more than 10X this minor punishment.

Sometimes there really is no justice in the world.

Our day is coming.

NAVB came back swinging today strong into the close.

GLTA.

Thanks.

GLTA.

Is .30 a base here or are .25 and .20 right around the corner?

Much appreciated...

DARN this volume is low...are we about to explode? 56,858 shares as of 1:08PM?! I have never seen this with NAVB before.

GLTA.

I'm glad I always say, "Expect the unexpected with NAVB" because this extremely low volume would be very surprising otherwise.

GLTA.

Thanks umiak. One thought that I have is that if short covering continues or accelerates, we may have a nice base now in the 2.85-3.03 range just from short covering.

The way NAVB traded in the second half of August, I was fully expecting a moderate short increase today.

The next quarter will certainly be interesting.

GLTA.

The short interest report is out and another 930,000 shares have been covered bringing the short interest slightly under 20,000,000 shares short.

What do folks here think of this? I wonder how much short covered shares are reshorted to maintain a perpetual stranglehold on the pps.

I still expect the unexpected, no matter what.

GLTA.

Where are the shorts today?

2.96 X 2.97

Moving up is where we go, where we stop, no one can know. LOL.

GLTA.

The way NAVB started climbing today toward the closing bell is a likely sign that the stock is being heavily shorted and manipulated for most of the day, everyday. Perhaps news is coming tomorrow. And perhaps the short interest information will come out tonight and confirm my suspicion that shorting activity was heavy in the second half of August.

GLTA.

Thanks umiak.

The new short interest will be reported today or tomorrow. Based on all of the downside pressure we saw in the second half of August, I expect to see a rise of approximately 200,000 short shares, perhaps more.

Thanks umiak, you beat me to it. You know what I'm talking about.

It's time for the new IR firm to start hyping Navidea instead of longs like us. I still maintain that the GE $28 million line of credit makes NAVB a great investment, especially under 3.00.

GLTA.

I'm expecting some late day buying to move NAVB back toward 3.00.

Too much news recently with too little volume to accompany it.

Somthing has to give.

GLTA.

Even lower volume today. The shorts have no hope of covering at this volume. Will the volume today reach 300,000 shares with a closing price of 3.04?

Super low volume today. I won't be surprised if the volume for the day exceeds 400,000 shares with a ton of trading in the next 23 minutes - and a close at 2.97.

GLTA.

I added 6,000 shares and have no doubt that I will up at least 10-15% within 2 months at the latest (maybe even this week) if the right catalysts are announced.

The shorts continue to create opportunity.

GLTA.